Aducanumab, a clinical treatment drug, primed to treat those with early symptoms of Alzheimer’s, recently went into Phase 1B clinical studies trial. Recently, the firm responsible for the manufacturing of the clinical treatment drugs, Biogen Inc. (NASDAQ:BIIB) released the data obtained from the Phase 1B trial. The data will be...
Fitbit Inc (NYSE:FIT), a global leader in wearable bands is looking for online business in Indian markets from July 1st, 2015.The Company is targeting all types of customers ranging from daily wear customers to performance athletes by introducing in four wearable bands in the market. The Vice-President and general manager,...
Novavax, Inc. (NASDAQ:NVAX) reported the commencement of a Phase II clinical study of its RSV F Vaccine in people 60 years of age and older. The goal of the study is to assess immunogenicity and safety to one and two dosage plan of the RSV F Vaccine, without and...
Novavax, Inc. (NASDAQ:NVAX) revenue in Q1 2017 jumped 35% to $5.7 million, as against $4.2 million for the equivalent period in 2016, mainly due to increased revenue posted under the BMGF grant pertaining to ongoing Prepare clinical study. Net Loss came at $43.9 million in Q1 2017 against a...
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), is a biopharmaceutical company, which mainly focuses on global immunology, today announced the successful results of Voclosporin, in the treatment of Japanese patients. The successful results pertained from the Phase I studies of this treatment process, indicate a strong evaluation, that the company will proceed to...
Shares of Del Mar Pharmaceuticals Inc. (NASDAQ:DMPI) last traded at $2.26. (NASDAQ:DMPI) performance year to date is -29.13%. The 200 day simple moving average is -44.45%. The 200 SMA is considered a major indicator by market analysts and traders for determining the long-term trend. The price in the market...
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has announced that it would be holding an investor conference call, to discuss its financial results for the 1Q2017, on May 10, 2017, at 8:30 am, ET. The call would be available via webcast as well. The company has stated that it would discuss the...
Celgene Corporation (NASDAQ:CELG) posted fourth quarter results, beating profit predictions but missing sales projections slightly. The firm continues to move on growth track while the stock still looks inexpensive. It is trading around $116 right now, up over 2% in the last trading session. Total revenues in the last...
Dallas, Texas 10/31/2013 (Financialstrend) - The $71.51 million market capitalized biotech firm Oragenics Inc (NYSEMKT:OGEN) reported its 3Q operations results on October 24.  Post the announcement, the stock had jumped up 8% before letting go of all its gains during trading rest of the week. Its top selling product ProBiora3...
Dallas, Texas 09/18/2013 (Financialstrend) - On August 26, Amarin Corporation plc (ADR) (NASDAQ:AMRN) announced that it had submitted a supplementary new drug application to FDA seeking approval for its key target drug Novasep. It has applied for this approval through its subsidiary Finorga. Thanks to this disclosure, the share...